Single cells were separated into CD44+CD133+ and ΔCD44+CD133+ fractions using FACS, and purified CD44+CD133+ cells were then injected into secondary recipient NSG mice to verify whether these subpopulations were still capable of initiating tumor formation. The gene discussed is PROM1; the disease is neoplasm.